Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
29.88
-0.95 (-3.08%)
At close: Mar 20, 2026, 4:00 PM EDT
29.88
0.00 (0.00%)
After-hours: Mar 20, 2026, 4:23 PM EDT
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
563.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Zevra Therapeutics | 106.47M |
| MeiraGTx Holdings | 27.42M |
| DBV Technologies | 5.50M |
| Upstream Bio | 2.80M |
| ProKidney | 744.00K |
| Allogene Therapeutics | 22.00K |
TECX News
- 14 days ago - Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 21 days ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 25 days ago - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - GlobeNewsWire
- 5 weeks ago - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 - GlobeNewsWire
- 4 months ago - Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point - Seeking Alpha
- 5 months ago - Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript - Seeking Alpha
- 5 months ago - Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewsWire
- 7 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire